The NMDA receptor antagonist MK-801 increases morphine catalepsy and lethality
- 31 March 1991
- journal article
- research article
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 38 (3) , 673-675
- https://doi.org/10.1016/0091-3057(91)90032-w
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The noncompetitive N-methyl-D-aspartate antagonists, MK-801, phencyclidine and ketamine, increase the potency of general anestheticsPharmacology Biochemistry and Behavior, 1990
- Regional Neuroprotective Effects of the NMDA Receptor Antagonist MK-801 (Dizocilpine) in Hypoglycemic Brain DamageJournal of Cerebral Blood Flow & Metabolism, 1990
- Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's diseaseTrends in Neurosciences, 1989
- Synthetic opioids compared with morphine and ketamine: Catalepsy, cross-tolerance and interactions in the ratNeuropharmacology, 1989
- Effects of NMDA antagonists, MK-801 and CPP, upon local cerebral glucose useBrain Research, 1989
- The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptorEuropean Journal of Pharmacology, 1989
- Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidineEuropean Journal of Pharmacology, 1989
- Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in ratsPharmacology Biochemistry and Behavior, 1989
- Enhancement of opioid cataleptic response by cortical frontal deafferentation or intrastriatal injection of NMDA-receptor antagonistsBrain Research, 1988
- Excitatory amino acids in the brain - focus on NMDA receptorsTrends in Neurosciences, 1987